A5054925768- Immune cells in cancer
- Cancer Immunotherapy and Biomarkers
- Chemokine receptors and signaling
- Atherosclerosis and Cardiovascular Diseases
- Cancer Cells and Metastasis
- Single-cell and spatial transcriptomics
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
While immunotherapies such as immune checkpoint blockade and adoptive T-cell therapy improve survival for a subset of human malignancies, many patients fail to respond. Phagocytes including dendritic cells (DC), monocytes, macrophages (MF) orchestrate innate adaptive responses against tumors. However, tumor-derived factors may limit immunotherapy effectiveness by altering phagocyte signal transduction, development, activity. Using Cytometry Time-of-Flight, we found that GCSF altered myeloid...
<p>CyTOF panels</p>
<p>Supplementary Figure S2 compares the immune cell content in peripheral blood and spleens from immunocompetent, immunocompromised G-CSFR-/- mice harboring MT or MTG-CSF-/- tumors.</p>
<p>Supplementary Figure S4 shows that G-CSF and G-CSFR signaling inhibit DC development activation, in DCs derived a OP9-DLL1 co-culture system.</p>
<p>Supplementary Figure S3 shows deep phenotyping of Neut/MDSCs and B cells in the bone marrow mice bearing MT or MTG-CSF-/- tumors, using FlowSOM applied tSNE maps.</p>
<p>Supplementary Figure S1 shows the characterization of MT and MTG-CSF-/- cell lines tumors, including surface protein expression, tumor volume/weight, immune subset content. Composition cells in blood spleen mice is also shown.</p>
<p>Flow cytometry antibodies</p>
<div><p>While immunotherapies such as immune checkpoint blockade and adoptive T-cell therapy improve survival for a subset of human malignancies, many patients fail to respond. Phagocytes including dendritic cells (DC), monocytes, macrophages (MF) orchestrate innate adaptive responses against tumors. However, tumor-derived factors may limit immunotherapy effectiveness by altering phagocyte signal transduction, development, activity. Using Cytometry Time-of-Flight, we found that...
<p>Flow cytometry antibodies</p>
<p>Supplementary Figure S2 compares the immune cell content in peripheral blood and spleens from immunocompetent, immunocompromised G-CSFR-/- mice harboring MT or MTG-CSF-/- tumors.</p>
<div><p>While immunotherapies such as immune checkpoint blockade and adoptive T-cell therapy improve survival for a subset of human malignancies, many patients fail to respond. Phagocytes including dendritic cells (DC), monocytes, macrophages (MF) orchestrate innate adaptive responses against tumors. However, tumor-derived factors may limit immunotherapy effectiveness by altering phagocyte signal transduction, development, activity. Using Cytometry Time-of-Flight, we found that...
<p>CyTOF panels</p>
<p>Supplementary Figure S4 shows that G-CSF and G-CSFR signaling inhibit DC development activation, in DCs derived a OP9-DLL1 co-culture system.</p>
<p>Supplementary Figure S3 shows deep phenotyping of Neut/MDSCs and B cells in the bone marrow mice bearing MT or MTG-CSF-/- tumors, using FlowSOM applied tSNE maps.</p>
<p>Supplementary Figure S1 shows the characterization of MT and MTG-CSF-/- cell lines tumors, including surface protein expression, tumor volume/weight, immune subset content. Composition cells in blood spleen mice is also shown.</p>